Martin H. Voss, MD, on Bringing Different Disciplines Together at IKCS
The medical oncologist discusses the different talks that were presented at the International Kidney Cancer Symposium in Miami.
Martin H. Voss, MD, from Memorial Sloan Kettering Cancer Center, discussed the various talks being presented at the International Kidney Cancer Symposium, held November 15-16, in Miami.
Transcription:
I’m excited to see new therapeutic strategies being discussed and I think this meeting has come a long way to actually bring different disciplines together. So, you know, we will be seeing the discussion of new targets in terms of new clinical data, but there’s also great talks that I’ve been looking forward to from laboratory investigators telling us about their efforts identifying new targets from a basic science perspective.
Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors
A 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation was 88%.
Belzutifan Improves PFS Across Subgroups for Advanced ccRCC
July 12th 2024“In LITESPARK-005, PFS and response rates favored belzutifan vs everolimus across [several patient subgroups, including] IMDC risk, number of prior lines [of therapy], and number of prior VEGF TKIs, specifically,” said Laurence Albiges, MD, PhD.
